<DOC>
	<DOCNO>NCT03074019</DOCNO>
	<brief_summary>The purpose clinical trial ass efficacy novel prebiotic , XOS95 , two different dosage , comparison placebo assess shift microbial population 8 week supplementation , assess change abundance microbial population .</brief_summary>
	<brief_title>Pilot Study Effect XOS95 Human Gut Microbiome</brief_title>
	<detailed_description />
	<criteria>Male female adult age 18 60 ( inclusive ) Healthy determine medical history Nonsmoker , exsmoker ≥6 month Body mass index 18.5 27.5kg/m2 ( inclusive ) Female subject childbearing potential [ i.e . surgically sterilize postmenopausal ( great one year since last menses ) ] must negative urine pregnancy test must use effective birth control method , define : Continuous use oral long act inject contraceptive least 2 month prior study entry , Use intrauterine device implantable contraceptive , Use double barrier method birth control , Abstinence heterosexual intercourse Willing avoid alcohol consumption 24 h prior every clinic visit Willing maintain regimen medication supplement know alter GI function ( include , limited , iron supplement , calcium , antidepressant ) Willing maintain stable body weight , activity level dietary pattern except use study product , direct Willing able provide inform write consent Pregnancy lactation , subject unwilling take appropriate contraceptive duration study Use prescription nonsteroidal antiinflammatory drug ( daily use counter nonsteroidal antiinflammatory drug &gt; 1month ) , steroid , corticosteroid , prescription antiinflammatory drug within 3 month prior visit 1 Individuals take counter prescription medication , include natural health product , may alter lipid profile include , limited fish oil ( omega3 fatty acid ) , statins , fibrates , bile acid exchanger resin , phytosterols , niacin analogue , carnitine , polyglucosamines ( Chitosan ) lipidbinding ingredient within 3 month prior visit 1 Individuals take counter prescription medication , include natural health product may alter blood glucose ( e.g . biguanides ( Metformin ) , Alphalipoic Acid ( ALA ) , Gymnema sylvestre ) insulin modulate medication ( e.g . sulfonylurea , meglitinides , Dphenylalanine derivatives , thiazolidinediones , DPP4 inhibitor , alphaglucosidase inhibitor , bile acid sequestrants within 3 month prior visit 1 Use proton pump inhibitor medication inhibit peristaltic movement ( e.g . opioids , loperamide ) Unstable use ( i.e . initiation change dose ) antihypertensive medication thyroid hormone replacement medication within 3 month prior visit 1 Use weightloss program weightloss medication ( prescription overthe counter ) include , limited , lipase inhibitor , within 3 month prior visit Use counter prescription laxatives stool softener within 1 month prior baseline ( V2 ) Use antibiotic ( topical ) within 2 month prior baseline ( V2 ) Use prebiotic fiber supplement ( e.g . fructans galactooligosaccharides ( FOS , GOS ) , psyllium , fiber , inulin , glucomannan , acacia fiber/gum ) probiotic supplement ( i.e . live microorganism ) within 4 week baseline ( V2 ) Consumption specific functional prebiotic probioticrich food within 4 week baseline ( V2 ) ( Appendix 3 ) History blood clot disorder use coagulationinhibiting drug ( e.g . warfarin ) Individuals achlorhydria Presence major disease diabetes , gastrointestinal , endocrine , cardiovascular , pancreatic , renal , liver disease Chronic diarrhea constipation , irritable bowel syndrome , celiac disease , glutensensitive enteropathy , inflammatory bowel disease Abdominal gastrointestinal surgery within previous 12 month plan abdominal gastrointestinal surgery procedure colonoscopy next 4 month Recent gastrointestinal foodborne illness ( within 1 month prior visit 1 ) History neurological disease ( e.g . Parkinson 's disease , stroke , traumatic brain injury , etc . ) History cancer ( exclude nonmelanoma skin cancer basal cell carcinoma ) past 5 year Uncontrolled hypertension define seat rest systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg Abnormal laboratory test result clinical significance , include , limited ALT AST ≥1.5X upper limit normal screening ( visit 1 ) Presence history ( past 6 month ) alcohol drug abuse ; alcohol use &gt; 2 standard alcoholic drink per day Extreme dietary habit ( e.g . vegan low carbohydrate diet , glutenfree diet , low FODMAP diet ) Subject know allergy intolerance test product placebo Subject unwilling unable abide requirement protocol Any condition would interfere subject 's ability comply study instruction , might confound interpretation study , put subject risk Subject take investigational health product participate research study within 30 day prior first study visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>